NCT02092909: A reported trial by Idera Pharmaceuticals, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02092909 |
|---|---|
| Title | Phase 1/2 Open-Label, Multiple-dose, Dose-escalation Study to Evaluate the Safety and Tolerability of IMO-8400 in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2014 |
| Completion date | April 30, 2017 |
| Required reporting date | April 30, 2018, midnight |
| Actual reporting date | March 22, 2018 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | None |